These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34754245)

  • 21. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer.
    Shen J; Hruby GW; McKiernan JM; Gurvich I; Lipsky MJ; Benson MC; Santella RM
    Prostate; 2012 Sep; 72(13):1469-77. PubMed ID: 22298119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma.
    Schaefer A; Jung M; Mollenkopf HJ; Wagner I; Stephan C; Jentzmik F; Miller K; Lein M; Kristiansen G; Jung K
    Int J Cancer; 2010 Mar; 126(5):1166-76. PubMed ID: 19676045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High microRNA-28-5p expression in colorectal adenocarcinoma predicts short-term relapse of node-negative patients and poor overall survival of patients with non-metastatic disease.
    Tsiakanikas P; Kontos CK; Kerimis D; Papadopoulos IN; Scorilas A
    Clin Chem Lab Med; 2018 May; 56(6):990-1000. PubMed ID: 29688883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
    Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
    J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer.
    Papadaki C; Stoupis G; Tsalikis L; Monastirioti A; Papadaki M; Maliotis N; Stratigos M; Mastrostamatis G; Mavroudis D; Agelaki S
    Oncotarget; 2019 Jan; 10(9):966-981. PubMed ID: 30847025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations of high expression of miR-106b-5p detected from FFPE sample with poor prognosis of RCC patients.
    Liu K; Pan X; Peng X; Zhang C; Li H; Guan X; Xu W; Xu J; Zhao L; Wang T; Lai Y
    Pathol Res Pract; 2019 Jun; 215(6):152391. PubMed ID: 31076282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative analysis of epi-miRNA expression levels in local/locally advanced and metastatic prostate cancer patients.
    Gurbuz V; Kiliccioglu I; Dikmen AU; Bilen CY; Sozen S; Konac E
    Gene; 2020 Oct; 758():144963. PubMed ID: 32683077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Potential of hsa-mir-106b-5p as Liquid Biomarker in Prostate Cancer Patients in Indonesia.
    Bonnu CH; Ramadhani AN; Saputro RB; Sesotyosari SL; Danarto R; Astuti I; Haryana SM
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):837-842. PubMed ID: 33773548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients.
    Li Z; Ma YY; Wang J; Zeng XF; Li R; Kang W; Hao XK
    Onco Targets Ther; 2016; 9():139-48. PubMed ID: 26770063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma.
    Romani C; Salviato E; Paderno A; Zanotti L; Ravaggi A; Deganello A; Berretti G; Gualtieri T; Marchini S; D'Incalci M; Mattavelli D; Piazza C; Bossi P; Romualdi C; Nicolai P; Bignotti E
    Theranostics; 2021; 11(6):2987-2999. PubMed ID: 33456584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-132/212 Upregulation Inhibits TGF-β-Mediated Epithelial-Mesenchymal Transition of Prostate Cancer Cells by Targeting SOX4.
    Fu W; Tao T; Qi M; Wang L; Hu J; Li X; Xing N; Du R; Han B
    Prostate; 2016 Dec; 76(16):1560-1570. PubMed ID: 27527117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-106b promotes colorectal cancer cell migration and invasion by directly targeting DLC1.
    Zhang GJ; Li JS; Zhou H; Xiao HX; Li Y; Zhou T
    J Exp Clin Cancer Res; 2015 Jul; 34(1):73. PubMed ID: 26223867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative and Absolute Expression Analysis of MicroRNAs Associated with Luminal A Breast Cancer- A Comparison.
    Arabkari V; Clancy E; Dwyer RM; Kerin MJ; Kalinina O; Holian E; Newell J; Smith TJ
    Pathol Oncol Res; 2020 Apr; 26(2):833-844. PubMed ID: 30840191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of pelvic lymph node irradiation in salvage therapy for patients with prostate cancer with a biochemical relapse following radical prostatectomy.
    Kim BS; Lashkari A; Vongtama R; Lee SP; Parker RG
    Clin Prostate Cancer; 2004 Sep; 3(2):93-7. PubMed ID: 15479492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.
    Alunni-Fabbroni M; Majunke L; Trapp EK; Tzschaschel M; Mahner S; Fasching PA; Fehm T; Schneeweiss A; Beck T; Lorenz R; Friedl TWP; Janni W; Rack B;
    BMC Cancer; 2018 Feb; 18(1):141. PubMed ID: 29409452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role.
    Cochetti G; Poli G; Guelfi G; Boni A; Egidi MG; Mearini E
    Onco Targets Ther; 2016; 9():7545-7553. PubMed ID: 28008272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.
    Stephan C; Jung M; Rabenhorst S; Kilic E; Jung K
    Clin Chem Lab Med; 2015 Jun; 53(7):1109-18. PubMed ID: 25720086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification.
    Al-Kafaji G; Said HM; Alam MA; Al Naieb ZT
    Oncol Lett; 2018 Jul; 16(1):1357-1365. PubMed ID: 30061955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
    Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postoperative adjuvant and salvage radiotherapy for prostate cancer: impact on freedom from biochemical relapse and survival.
    Pacholke HD; Wajsman Z; Algood CB; Neulander EZ; Morris CG; Zlotecki RA
    Urology; 2004 Nov; 64(5):982-6. PubMed ID: 15533490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.